PEGylation of Interferon-β-1a

A promising strategy in multiple sclerosis

Bernd C. Kieseier, Peter Calabresi

Research output: Contribution to journalArticle

Abstract

Achieving optimal patient benefit from biological therapies can be hindered by drug instability, rapid clearance requiring frequent dosing or potential immune reactions. One strategy for addressing these challenges is drug modification through PEGylation, a well established process by which one or more molecules of polyethylene glycol (PEG) are covalently attached to a biological or small-molecule drug, effectively transforming it into a therapy with improved pharmacokinetic and pharmacodynamic properties. Numerous PEGylated therapeutics are currently available, all of which have at least comparable efficacy, safety and tolerability to their unmodified forms. A PEGylated form of interferon-β-1a (PEG-IFNβ-1a) is being developed to address an unmet medical need for safer, more effective and more convenient therapies for multiple sclerosis (MS). Phase I study data suggest that PEG-IFNβ-1a should provide patients with a first-line therapy with a more convenient dosing regimen while maintaining the established efficacy, safety and tolerability of presently available IFNβ-1a. The ongoing global ADVANCE phase III study will determine the clinical efficacy of PEG-IFNβ-1a in patients with relapsing MS.

Original languageEnglish (US)
Pages (from-to)205-214
Number of pages10
JournalCNS Drugs
Volume26
Issue number3
DOIs
StatePublished - 2012

Fingerprint

Interferons
Multiple Sclerosis
Pharmaceutical Preparations
Safety
Biological Therapy
Therapeutics
Pharmacokinetics

Keywords

  • Multiple-sclerosis
  • PEG-interferon-beta-1a.

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Clinical Neurology

Cite this

PEGylation of Interferon-β-1a : A promising strategy in multiple sclerosis. / Kieseier, Bernd C.; Calabresi, Peter.

In: CNS Drugs, Vol. 26, No. 3, 2012, p. 205-214.

Research output: Contribution to journalArticle

@article{89f6f682224e4838b5a91f74e43b9452,
title = "PEGylation of Interferon-β-1a: A promising strategy in multiple sclerosis",
abstract = "Achieving optimal patient benefit from biological therapies can be hindered by drug instability, rapid clearance requiring frequent dosing or potential immune reactions. One strategy for addressing these challenges is drug modification through PEGylation, a well established process by which one or more molecules of polyethylene glycol (PEG) are covalently attached to a biological or small-molecule drug, effectively transforming it into a therapy with improved pharmacokinetic and pharmacodynamic properties. Numerous PEGylated therapeutics are currently available, all of which have at least comparable efficacy, safety and tolerability to their unmodified forms. A PEGylated form of interferon-β-1a (PEG-IFNβ-1a) is being developed to address an unmet medical need for safer, more effective and more convenient therapies for multiple sclerosis (MS). Phase I study data suggest that PEG-IFNβ-1a should provide patients with a first-line therapy with a more convenient dosing regimen while maintaining the established efficacy, safety and tolerability of presently available IFNβ-1a. The ongoing global ADVANCE phase III study will determine the clinical efficacy of PEG-IFNβ-1a in patients with relapsing MS.",
keywords = "Multiple-sclerosis, PEG-interferon-beta-1a.",
author = "Kieseier, {Bernd C.} and Peter Calabresi",
year = "2012",
doi = "10.2165/11596970-000000000-00000",
language = "English (US)",
volume = "26",
pages = "205--214",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "3",

}

TY - JOUR

T1 - PEGylation of Interferon-β-1a

T2 - A promising strategy in multiple sclerosis

AU - Kieseier, Bernd C.

AU - Calabresi, Peter

PY - 2012

Y1 - 2012

N2 - Achieving optimal patient benefit from biological therapies can be hindered by drug instability, rapid clearance requiring frequent dosing or potential immune reactions. One strategy for addressing these challenges is drug modification through PEGylation, a well established process by which one or more molecules of polyethylene glycol (PEG) are covalently attached to a biological or small-molecule drug, effectively transforming it into a therapy with improved pharmacokinetic and pharmacodynamic properties. Numerous PEGylated therapeutics are currently available, all of which have at least comparable efficacy, safety and tolerability to their unmodified forms. A PEGylated form of interferon-β-1a (PEG-IFNβ-1a) is being developed to address an unmet medical need for safer, more effective and more convenient therapies for multiple sclerosis (MS). Phase I study data suggest that PEG-IFNβ-1a should provide patients with a first-line therapy with a more convenient dosing regimen while maintaining the established efficacy, safety and tolerability of presently available IFNβ-1a. The ongoing global ADVANCE phase III study will determine the clinical efficacy of PEG-IFNβ-1a in patients with relapsing MS.

AB - Achieving optimal patient benefit from biological therapies can be hindered by drug instability, rapid clearance requiring frequent dosing or potential immune reactions. One strategy for addressing these challenges is drug modification through PEGylation, a well established process by which one or more molecules of polyethylene glycol (PEG) are covalently attached to a biological or small-molecule drug, effectively transforming it into a therapy with improved pharmacokinetic and pharmacodynamic properties. Numerous PEGylated therapeutics are currently available, all of which have at least comparable efficacy, safety and tolerability to their unmodified forms. A PEGylated form of interferon-β-1a (PEG-IFNβ-1a) is being developed to address an unmet medical need for safer, more effective and more convenient therapies for multiple sclerosis (MS). Phase I study data suggest that PEG-IFNβ-1a should provide patients with a first-line therapy with a more convenient dosing regimen while maintaining the established efficacy, safety and tolerability of presently available IFNβ-1a. The ongoing global ADVANCE phase III study will determine the clinical efficacy of PEG-IFNβ-1a in patients with relapsing MS.

KW - Multiple-sclerosis

KW - PEG-interferon-beta-1a.

UR - http://www.scopus.com/inward/record.url?scp=84856894168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856894168&partnerID=8YFLogxK

U2 - 10.2165/11596970-000000000-00000

DO - 10.2165/11596970-000000000-00000

M3 - Article

VL - 26

SP - 205

EP - 214

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - 3

ER -